1. Home
  2. News

Cyto-Facto Inc. has concluded Memorandum of Understanding (MOU) with SanBio Co, Ltd.

September 27, 2024

We are pleased to announce that Cyto-Facto Inc. (Head Office: Chuo-ku, Tokyo; President and CEO: Shin Kawamata; referred to as "Cyto-Facto"), a CDMO engaged in the contract manufacturing of gene and cell preparations, signed a Memorandum of Understanding (MOU) with SanBio Co, Ltd. (Head Office: Chuo-ku, Tokyo; President and CEO: Keita Mori; referred to as "SanBio"). Both companies have exchanged information through quality and characteristic tests, and have confirmed the benefits of cooperation between the two companies.

This Memorandum of Understanding (MOU) is based on a mutual cooperative attitude of Cyto-Facto and SanBio to contribute to the expansion and development of each other's businesses and profits through the effective use of technology, know-how, management resources. Specifically, the two companies will discuss and implement cooperation with respect to testing the quality and characteristics of the regenerative medicine product "Acugo®“manufactured and marketed by SanBio, the two companies will discuss and implement collaboration, etc., including appropriate evaluation and review of the information provided by both companies.

Cyto-Facto will continue to value the collaboration with SanBio to promote the use of high quality regenerative medicine products and gene/cell preparations backed by scientifically accurate quality control tests and characteristic tests.

【About SanBio】

SanBio is engaged in the research, development, manufacturing and marketing of regenerative medicine products.

In July 2024, SanBio received a conditional and time-limited manufacturing and marketing approval for its lead product SB623, Acugo® under the accelerated designation system for the treatment of chronic motor paralysis associated with traumatic brain injury. SanBio will continue to focus on the treatment of diseases in the central nervous system that cannot be treated with existing medical treatments and pharmaceuticals and for which there is a high unmet medical need.
More information about SanBio Group, headquartered in Tokyo, Japan, with subsidiaries in California, please visit https://www.sanbio.com/en/.

【About Cyto-Facto】

Cyto-Facto specializes in CMO/CDMO business, contract quality testing, and manufacturing consultancy for gene and cell products. In addition to the commercial manufacturing of the world's first CAR-T cell, Kymriah® for intravenous infusion, Cyto-Facto has conducted investigational manufacturing and process development for gene and cell products in Japan and overseas. As a leader n GMP-compliant manufacturing of gene and cell products, Cyto-Facto is also involved in the development and implementation of integrated manufacturing management systems in this field.
Website: https://www.cytofacto.com/en/